Compare Stocks: EVO, ALMR, BLFS, and FTRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$34.82 +5.6%	$26.14	$18.84 ▼ $38.54	$2.42B	N/A	311,934 shs	172,028 shs
BLFS BioLife Solutions	$36.64 +4.9%	$29.72	$17.86 ▼ $36.91	$1.79B	1.93	685,745 shs	217,473 shs
EVO Evotec	$1.94 +1.3%	$2.34	$1.89 ▼ $4.27	$688.40M	1.96	96,400 shs	10,298 shs
FTRE Fortrea	$18.34 +4.2%	$17.77	$7.40 ▼ $21.39	$1.74B	1.99	1.52 million shs	104,311 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+2.58%	-9.87%	+27.01%	+63.49%	+3,295,999,900.00%
BLFS BioLife Solutions	-1.44%	+0.34%	+19.86%	+45.58%	+42.61%
EVO Evotec	-2.55%	-9.05%	-2.55%	-32.75%	-48.10%
FTRE Fortrea	-2.76%	-9.84%	-0.90%	+28.47%	+122.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$34.82 +5.6%	$26.14	$18.84 ▼ $38.54	$2.42B	N/A	311,934 shs	172,028 shs
BLFS BioLife Solutions	$36.64 +4.9%	$29.72	$17.86 ▼ $36.91	$1.79B	1.93	685,745 shs	217,473 shs
EVO Evotec	$1.94 +1.3%	$2.34	$1.89 ▼ $4.27	$688.40M	1.96	96,400 shs	10,298 shs
FTRE Fortrea	$18.34 +4.2%	$17.77	$7.40 ▼ $21.39	$1.74B	1.99	1.52 million shs	104,311 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+2.58%	-9.87%	+27.01%	+63.49%	+3,295,999,900.00%
BLFS BioLife Solutions	-1.44%	+0.34%	+19.86%	+45.58%	+42.61%
EVO Evotec	-2.55%	-9.05%	-2.55%	-32.75%	-48.10%
FTRE Fortrea	-2.76%	-9.84%	-0.90%	+28.47%	+122.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMR Alamar Biosciences	2.43	Hold	$31.80	-8.67% Downside
BLFS BioLife Solutions	2.18	Hold	$31.38	-14.37% Downside
EVO Evotec	2.20	Hold	$3.00	55.04% Upside
FTRE Fortrea	2.33	Hold	$20.75	13.17% Upside

Current Analyst Ratings Breakdown

Latest EVO, ALMR, BLFS, and FTRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ALMR Alamar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/11/2026	ALMR Alamar Biosciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $32.00
8/11/2026	ALMR Alamar Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$32.00 ➝ $35.00
8/10/2026	BLFS BioLife Solutions	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/4/2026	FTRE Fortrea	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$19.00 ➝ $23.00
8/4/2026	FTRE Fortrea	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	FTRE Fortrea	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $22.00
7/30/2026	FTRE Fortrea	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$20.00
7/30/2026	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
7/30/2026	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $22.00
7/30/2026	FTRE Fortrea	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$19.00 ➝ $26.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMR Alamar Biosciences	$74.21M	32.56	N/A	N/A	N/A	∞
BLFS BioLife Solutions	$106.69M	16.78	$0.24 per share	153.16	$7.72 per share	4.75
EVO Evotec	$891.97M	0.77	N/A	N/A	$2.59 per share	0.75
FTRE Fortrea	$2.72B	0.64	$10.42 per share	1.76	$6.10 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMR Alamar Biosciences	-$29.82M	-$1.96	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	-$4.59M	$1.16	31.67	229.00	N/A	53.29%	2.70%	2.49%	11/5/2026 (Estimated)
EVO Evotec	-$117.12M	N/A	N/A	N/A	N/A	-26.20%	-24.93%	-11.35%	11/5/2026 (Estimated)
FTRE Fortrea	-$986.20M	-$0.91	N/A	17.30	0.42	-3.18%	10.72%	2.17%	11/4/2026 (Estimated)

Latest EVO, ALMR, BLFS, and FTRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ALMR Alamar Biosciences	-$0.36	-$0.22	+$0.14	-$0.22	N/A	$29.43 million
8/6/2026	Q2 2026	BLFS BioLife Solutions	$0.0313	$0.91	+$0.8788	$0.91	$27.80 million	$28.47 million
7/29/2026	Q2 2026	FTRE Fortrea	$0.1804	$0.23	+$0.0496	-$0.14	$647.57 million	$678.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMR Alamar Biosciences	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMR Alamar Biosciences	0.03	11.85	10.23
BLFS BioLife Solutions	N/A	9.69	7.14
EVO Evotec	0.62	2.33	2.21
FTRE Fortrea	1.98	0.96	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	93.24%
EVO Evotec	5.81%
FTRE Fortrea	N/A

Insider Ownership

Company	Insider Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	2.20%
EVO Evotec	N/A
FTRE Fortrea	0.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMR Alamar Biosciences	222	69.39 million	N/A	N/A
BLFS BioLife Solutions	440	48.86 million	47.78 million	Optionable
EVO Evotec	4,553	355.76 million	N/A	Not Optionable
FTRE Fortrea	14,300	95.10 million	94.41 million	Optionable

EVO, ALMR, BLFS, and FTRE Headlines

Recent News About These Companies

Fortrea Holdings Inc. (NASDAQ:FTRE) Receives $20.75 Average Target Price from Analysts

August 17 at 3:58 AM | americanbankingnews.com

Assenagon Asset Management S.A. Increases Stake in Fortrea Holdings Inc. $FTRE

August 14, 2026 | marketbeat.com

Drug development inputs & services stocks Q2 in review: Fortrea (NASDAQ:FTRE) vs peers

August 13, 2026 | msn.com

Fortrea (NASDAQ:FTRE) Trading Down 5.4% - Here's What Happened

August 12, 2026 | marketbeat.com

Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Consensus Recommendation of "Hold" from Analysts

August 12, 2026 | marketbeat.com

Fortrea (FTRE) Gains Traction in Turnaround

August 11, 2026 | insidermonkey.com

Ausbil Investment Management Ltd Sells 63,315 Shares of Fortrea Holdings Inc. $FTRE

August 11, 2026 | marketbeat.com

Fortrea Holdings Inc. (FTRE) Gets a Hold from Mizuho Securities

August 10, 2026 | theglobeandmail.com

Will Fortrea’s (FTRE) Higher 2026 Revenue Guidance and CFO Shift Recast Its Investment Narrative?

August 10, 2026 | finance.yahoo.com

Dimensional Fund Advisors LP Increases Stake in Fortrea Holdings Inc. $FTRE

August 9, 2026 | marketbeat.com

Fortrea (FTRE) Q2 2026 Earnings Call Transcript

August 8, 2026 | finance.yahoo.com

Anshul Thakral Sells 99,869 Shares of Fortrea (NASDAQ:FTRE) Stock

August 6, 2026 | marketbeat.com

Fortrea (NASDAQ:FTRE) Lowered to Hold Rating by Zacks Research

August 6, 2026 | marketbeat.com

Fortrea (NASDAQ:FTRE) Stock Price Down 5.7% - Time to Sell?

August 3, 2026 | marketbeat.com

Fortrea (NASDAQ:FTRE) Raised to Hold at William Blair

August 1, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 643,000 Shares of Fortrea Holdings Inc. $FTRE

August 1, 2026 | marketbeat.com

Fortrea (NASDAQ:FTRE) Upgraded by Wall Street Zen to Buy Rating

August 1, 2026 | marketbeat.com

Truist Financial Remains a Buy on Fortrea Holdings Inc. (FTRE)

July 31, 2026 | theglobeandmail.com

Barclays Keeps Their Hold Rating on Fortrea Holdings Inc. (FTRE)

July 31, 2026 | theglobeandmail.com

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know

July 31, 2026 | zacks.com

FTRE vs. ARGX: Which Stock Is the Better Value Option?

July 31, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EVO, ALMR, BLFS, and FTRE Company Descriptions

Alamar Biosciences NASDAQ:ALMR

$34.82 +1.86 (+5.64%)

As of 10:14 AM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

BioLife Solutions NASDAQ:BLFS

$36.64 +1.70 (+4.87%)

As of 10:32 AM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Evotec NASDAQ:EVO

$1.94 +0.03 (+1.31%)

As of 10:30 AM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Fortrea NASDAQ:FTRE

$18.34 +0.74 (+4.18%)

As of 10:32 AM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVO, ALMR, BLFS, and FTRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVO, ALMR, BLFS, and FTRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVO, ALMR, BLFS, and FTRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVO, ALMR, BLFS, and FTRE Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

Evotec NASDAQ:EVO

Fortrea NASDAQ:FTRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVO, ALMR, BLFS, and FTRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVO, ALMR, BLFS, and FTRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVO, ALMR, BLFS, and FTRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVO, ALMR, BLFS, and FTRE Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

Evotec NASDAQ:EVO

Fortrea NASDAQ:FTRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools